On Wednesday shares of Whiting Petroleum Corp. (NYSE:WLL) closed at $36.76. Company’s sales growth for last 5 years was 26.90% and EPS growth for next 5 years is recorded as -8.04%. Whiting Petroleum Corp. (NYSE:WLL) posted a quarterly loss of $106.1 million, or $0.63 per share, versus a year-ago profit of $109.1 million, or $0.92 per share. Excluding special items, Whiting Petroleum posted a loss of $0.23 per share, versus a year-ago profit of $1.06 per share.
GrubHub Inc. (NYSE:GRUB) in last trading activity fell -9.82% to close at $40.85. Company weekly performance is -10.89% while its quarterly performance stands at 18.44%. GrubHub Inc. (NYSE:GRUB) is -14.81% away from its 52 week high. GrubHub Inc. (NYSE:GRUB) reported first-quarter net income of $10.6 million. The Chicago-based company said it had net income of 12 cents per share.
On last trading day Monmouth Real Estate Investment Corp. (NYSE:MNR) fell -1.94% to close at $10.64. Its volatility for the week is 1.31% while volatility for the month is 1.37%. MNR’s sales growth for past 5 years was 9.80% and its EPS growth for past 5 years was 57.40%. Monmouth Real Estate Investment Corp. (NYSE:MNR) monthly performance is -4.23%. Monmouth Real Estate Investment Corp. (NYSE:MNR) declared its quarterly cash dividend on the Company’s Common Stock of $0.15 per share payable June 15, 2015, to shareholders of record at the close of business on May 15, 2015. The Company’s annual dividend rate on its Common Stock is $0.60 per share.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) has 0.10% insider ownership while its institutional ownership stands at 15.50%. In last trading activity company’s stock closed at $1.33. On 20 April, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced the presentation of data from clinical translational studies of the company’s phosphatidylserine (PS)-targeting immunotherapy bavituximab. Initial data from a pilot study of clinical translational ex vivo cultures show that bavituximab, both alone and with docetaxel, elicits evidence of a tumor-specific immune response in patients with human adenocarcinoma of the lung and that bavituximab exhibits an impact on tumors with negative PD-L1 expression.
On last trading day TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) advanced 2.47% to close at $4.15. Its volatility for the week is 8.29% while volatility for the month is 6.71%. TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) monthly performance is -8.59%. On 20 April, TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) and Merck (NYSE:MRK) announced they have entered into an oncology clinical study collaboration.